Fluoxetine, an SSRI used for depression, effectively inhibits NLRP3-ASC inflammasome activation and the release of inflammatory cytokines in retinal pigment epithelium (RPE) cells and macrophages, potentially mitigating dry AMD [70]. This evidence concerns the gene NLRP3 and depressive disorder.